Table 1 Baseline characteristics of the study population
Total (n = 1,273) | NO-OCAD (n = 1,061) | OCAD (n = 212) | KS Test p | p | |||
|---|---|---|---|---|---|---|---|
Age, y | 58.2(14.3) | 56.8(14.2) | 65.2(12.8) | 0.128 | 0.047 | ||
Male, n (%) | 692(54.4) | 558(52.6) | 134(63.2) | 0.005 | |||
Hypertension, n (%) | 0.074 | ||||||
Stage 1 | 55(4.3) | 52(4.9) | 3(1.4) | ||||
Stage 2 | 107(8.4) | 89(8.4) | 18(8.5) | ||||
Stage 3 | 1,111(87.3) | 920(86.7) | 191(90.1) | ||||
Diabetes mellitus, n (%) | 337(26.5) | 255(24.0) | 82(38.7) | 0.000 | |||
Current smoker, n (%) | 362(28.4) | 280(26.4) | 82(38.7) | 0.000 | |||
Hs-CRP | 1.0(0.5–2.3) | 1.0(0.5–2.2) | 1.1(0.5–2.8) | 0.000 | 0.134 | ||
eGFR (mL/min·1.73m2) | 88.6(24.7) | 97.7(28.0) | 84.3(25.4) | 0.568 | 0.144 | ||
LVEF, % | 59.0(58.0–59.0) | 59.0(58.0–59.0) | 59.0(58.0–59.0) | 0.000 | 0.022 | ||
TC, mmol/L | 4.8(4.1–5.5) | 4.8(4.5–5.5) | 4.8(4.0-5.5) | 0.009 | 0.652 | ||
TG, mmol/L | 1.4(1.0-2.1) | 1.4(1.0–2.0) | 1.6(1.1–2.2) | 0.000 | 0.043 | ||
HDL-C, mmol/L | 1.2(0.9–1.4) | 1.2(0.9–1.4) | 1.1(0.9–1.3) | 0.000 | 0.016 | ||
LDL-C, mmol/L | 2.6(2.2–3.1) | 2.6(2.2–3.1) | 2.6(2.1–3.2) | 0.006 | 0.814 | ||
CACS > 0, n (%) | 695(54.6) | 500(47.1) | 195(92.0) | 0.000 | |||
CACS, score | 2.2(0.0-116.0) | 0.0(0.0-43.5) | 292.0(58.3–745.0) | 0.000 | 0.000 | ||